Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Capricor Therapeutics (CAPR) over the last 2 years, with Sep 2025 value amounting to $2.6 million.

  • Capricor Therapeutics' Other Accumulated Expenses rose 26121.55% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 26121.55%. This contributed to the annual value of $435,712 for FY2024, which is 4257.12% up from last year.
  • Capricor Therapeutics' Other Accumulated Expenses amounted to $2.6 million in Q3 2025, which was up 80.88% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Other Accumulated Expenses registered a high of $2.6 million during Q3 2025, and its lowest value of $10,000 during Q4 2023.
  • Over the past 3 years, Capricor Therapeutics' median Other Accumulated Expenses value was $20,178 (recorded in 2023), while the average stood at $529,936.
  • In the last 5 years, Capricor Therapeutics' Other Accumulated Expenses slumped by 88.79% in 2023 and then spiked by 26,121.55% in 2025.
  • Over the past 4 years, Capricor Therapeutics' Other Accumulated Expenses (Quarterly) stood at $89,234 in 2022, then slumped by 88.79% to $10,000 in 2023, then spiked by 4,257.12% to $435,712 in 2024, then skyrocketed by 26,121.55% to $2.6 million in 2025.
  • Its Other Accumulated Expenses was $2.6 million in Q3 2025, compared to $1.4 million in Q2 2025 and $201,681 in Q1 2025.